# The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Source: https://onco.cc/trials/nct06254521/  
OnCo record `nct06254521` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab in colorectal cancer, run by First Affiliated Hospital of Guangxi Medical University, now recruiting.

## Summary

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer is a phase 2, interventional study registered as NCT06254521 by First Affiliated Hospital of Guangxi Medical University, with a registry enrolment figure of 60 participants, started 2024-02-22 and due to reach its primary completion in 2024-12-30. Interventions recorded: Tislelizumab combined with chemotherapy. Conditions listed: Rectal Cancer; Rectal Cancer Stage II; Rectal Cancer Stage III. Primary outcome: Pathological complete response (pCR) rate. Colorectal eligibility wording from the registry: "* Pathologically diagnosed MSS ((confirmed by microsatellite stable detection or next-generation target sequencing) or (confirmed by immunohistochemistry)) colon adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06254521
- Phase: 2
- Setting: Neoadjuvant Treatment of Locally Advanced MSS Rectal Cancer With Tislelizumab Combined With CAPOX Regimen: a Prospective, Single-arm, Single-center, Exploratory Phase II Clinical Study
- Sponsor: First Affiliated Hospital of Guangxi Medical University
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06254521: https://clinicaltrials.gov/study/NCT06254521

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06254521.json